APA (7th ed.) Citation

HM, C., PY, C., CH, C., & HC, T. (2021). Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study. Dove Medical Press.

Chicago Style (17th ed.) Citation

HM, Chang, Chou PY, Chou CH, and Tsai HC. Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study. Dove Medical Press, 2021.

MLA (8th ed.) Citation

HM, Chang, et al. Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study. Dove Medical Press, 2021.